KellyNGodbyMD
Oncology • Birmingham, ALAssociate Professor, Medicine, University of Alabama School of Medicine
Dr. Godby is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35249Phone+1 205-934-5038
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011- University of Alabama Medical CenterResidency, Internal Medicine, 2005 - 2008
Mercer University School of MedicineClass of 2005
Certifications & Licensure
AL State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- 21 citationsMinimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt
The Lancet. Haematology. 2023-11-01 - 5 citationsDrug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.Luciano J Costa, Smith Giri, Susan Bal, Gayathri Ravi, Kelly N Godby
British Journal of Haematology. 2023-03-01 - 29 citationsFamily history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresMaryAnn E. VanValkenburg, Gwendolyn I. Pruitt, Ilene Brill, Luciano J. Costa, Maryam Ehtsham
Cancer Causes & Control. 2016-01-01
Journal Articles
- Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific MortalityParameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology
Abstracts/Posters
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
